Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176227 | 1.00 | TSHR (0.47) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL176229 | 1.00 | TSHR (0.47) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL6422885 | 0.91 | TSHR (0.46) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL8242298 | 0.88 | SLC1A1 (0.45) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL14667033 | 0.88 | TSHR (0.47) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL666790 | 0.87 | GRIK1 (0.48) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL176228 | 0.87 | GRIK1 (0.48) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5141195 | 0.87 | TSHR (0.46) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL2519974 | 0.85 | KMT2A (0.48) | TSHRTDP1PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL2518196 | 0.85 | CYP2D6 (0.50) | TSHRTDP1MAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585973-B2 | Process for producing folic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-09-08 | — | — | US | claimed |
| US-20070142387-A1 | Process for producing folic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-06-21 | — | — | US | claimed |
| EP-1734044-A1 | PROCESS FOR PRODUCING FOLIC ACID DERIVATIVE | Japan Science and Technology Agency (JP) | 2006-12-20 | — | — | EP | claimed |
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7585973-B2 | Process for producing folic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7235585-B2 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20070142387-A1 | Process for producing folic acid derivatives | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1734044-A1 | PROCESS FOR PRODUCING FOLIC ACID DERIVATIVE | Japan Science and Technology Agency (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142387-A1 | Process for producing folic acid derivatives | DHFR, FOLR1, FOLR2 | TSHR 2754/4885TDP1 3169/4885PKM 890/4885 |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CNDP2, PNP, APRT | TSHR 4028/4885TDP1 689/4885PKM 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.